onc price
Whomever it was that said price doesn't matter has no regard for their fellow shareholders as I do not think that there is one person on this board who can agree with that statement especially from a company that has no clear path at this time. But wait there is hope in the New Year, all will become clear.
The only time price doesn't matter is if you know a BO is coming at a respectable price and most likely that would not even happen now. Also it doesn't matter how much management makes, that's a red herring and most likely will get another raise in 2024 with lots of options so they can at least keep up with the cost of living. Upset yes, and we have every right to be as we have no updates and no clear path going forward and with Andrew gone, so much for the BD side of things so most likely not much happening on that front. Will the next 3 weeks make all clear for everyone, I doubt it as there is never that much said that will affect the sp in anyway and that is just the way it is but wait there will be that glimmer of hope for the anticipation of a phase 3 sometime in 2024. And of course the panc folfirinox trial which is hopefully going to start in the first half of 2024 but then again will have no results until 2025. So what do we have to look forward to in 2024, we have no new trials that will make any difference, so the only hope is that we partner for real and that we actually start a phase 3 without such massive dilution that there is nothing for the shareholders. KInda think that the company (if they care about shareholders) should enact a poison pill so that no one can come in and take advantage of the doesn't matter what the sp is and take everyone out.
Yeah I am upset as something is not right at this stage of the game with so many hopes and promises that have never happened. Will it be different in 2024, I am sure some will tell us that the next 6-9 months will be transformative for the company because last time they said that it was with the sp going down about 60%. We are now almost at a one year low and not that far from a 2 year low so nothing for managment to be proud of when they talk about shareholder value all the time with nothing to show but more options and a raise. On the bright side, good thing we have a leading health care provider as our lead investor and shareholder.